| ADC Therapeutics operates as a clinical-stage oncology drug discovery and development company. Co. focuses on advancing highly potent and targeted antibody drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Co. serves customers in the United States, Switzerland, and the United Kingdom. The ADCT average annual return since 2020 is shown above.
The Average Annual Return on the ADCT average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ADCT average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ADCT average annual return calculation with any dividends reinvested as applicable (on ex-dates).